0001562180-19-005523.txt : 20191114
0001562180-19-005523.hdr.sgml : 20191114
20191114184608
ACCESSION NUMBER: 0001562180-19-005523
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191113
FILED AS OF DATE: 20191114
DATE AS OF CHANGE: 20191114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scheer David
CENTRAL INDEX KEY: 0001378585
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33095
FILM NUMBER: 191221991
MAIL ADDRESS:
STREET 1: ACHILLION PHARMACEUTICALS
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACHILLION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070336
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-624-7000
MAIL ADDRESS:
STREET 1: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-11-13
false
0001070336
ACHILLION PHARMACEUTICALS INC
ACHN
0001378585
Scheer David
C/O ACHILLION PHARMACEUTICALS, INC.
1777 SENTRY PARKWAY W, BLDG 14, STE 200
BLUE BELL
PA
19422
true
false
false
false
Common Stock
2019-11-13
4
M
false
20000.00
3.28
A
40000.00
D
Common Stock
2019-11-13
4
S
false
10485.00
6.3135
D
29515.00
D
Common Stock
63249.00
I
See footnote
Stock Option (Right to Buy)
3.28
2019-11-13
4
M
false
20000.00
0.00
D
2019-12-18
Common Stock
20000.00
0.00
D
Consists of shares held by Scheer Investment Holdings III, LLC. Mr Scheer is the Managing Member of Scheer Investment Holdings III, LLC. and as such may be deemed to have shared voting and investment power with respect to the shares held by Scheer Investment Holdings III, LLC. Mr. Scheer disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
/s/ Keri Lantz, attorney-in-fact
2019-11-14